[HTML][HTML] MicroRNAs in Huntington's disease: Diagnostic biomarkers or therapeutic agents?

X Dong, S Cong - Frontiers in cellular neuroscience, 2021 - frontiersin.org
MicroRNA (miRNA) is a non-coding single-stranded small molecule of approximately 21
nucleotides. It degrades or inhibits the translation of RNA by targeting the 3′-UTR. The …

[HTML][HTML] Why Woody got the blues: The neurobiology of depression in Huntington's disease

C Gubert, T Renoir, AJ Hannan - Neurobiology of disease, 2020 - Elsevier
Huntington's disease (HD) is an extraordinary disorder that usually strikes when individuals
are in the prime of their lives, as was the case for the influential 20th century musician …

A novel Huntington's disease assessment platform to support future drug discovery and development

J Wu, L Möhle, T Brüning, I Eiriz, M Rafehi… - International Journal of …, 2022 - mdpi.com
Huntington's disease (HD) is a lethal neurodegenerative disorder without efficient
therapeutic options. The inefficient translation from preclinical and clinical research into …

[HTML][HTML] Environmental stimulation in Huntington disease patients and animal models

A Novati, HP Nguyen, J Schulze-Hentrich - Neurobiology of Disease, 2022 - Elsevier
While Huntington disease (HD) is caused solely by a polyglutamine expansion in the
huntingtin gene, environmental factors can influence HD onset and progression. Here, we …

Recent developments in the management of Huntington's disease

SJ Devadiga, SS Bharate - Bioorganic Chemistry, 2022 - Elsevier
Huntington's disease (HD) is a rare, incurable, inherited neurodegenerative disorder
manifested by chorea, hyperkinetic, and hypokinetic movements. The FDA has approved …

A clinical study and future prospects for bioactive compounds and semi-synthetic molecules in the therapies for Huntington's disease

MR Islam, MH Jony, GK Thufa, S Akash, PS Dhar… - Molecular …, 2024 - Springer
A neurodegenerative disorder (ND) refers to Huntington's disease (HD) which affects
memory loss, weight loss, and movement dysfunctions such as chorea and dystonia. In the …

Treatment of depression in Huntington's disease: a systematic review

SA Zadegan, F Ramirez, KS Reddy… - The Journal of …, 2024 - Am Neuropsych Assoc
Depression is a common psychiatric disorder among individuals with Huntington's disease
(HD). Depression in HD and major depressive disorder appear to have different …

Pharmacogenetics in the treatment of Huntington's disease: review and future perspectives

X García-González, E Cubo, L Simón-Vicente… - Journal of Personalized …, 2023 - mdpi.com
Huntington's disease (HD) is an autosomal dominant progressive brain disorder, caused by
a pathological expansion of a CAG repeat that encodes the huntingtin gene. This genetic …

[HTML][HTML] A touchscreen motivation assessment evaluated in Huntington's disease patients and R6/1 model mice

CJ Heath, C O'Callaghan, SL Mason… - Frontiers in …, 2019 - frontiersin.org
Apathy is pervasive across many neuropsychiatric disorders but is poorly characterized
mechanistically, so targeted therapeutic interventions remain elusive. A key impediment has …

Genetic risk for Huntington Disease and reproductive decision‐making: A systematic review

N Fahy, C Rice, N Lahiri, R Desai, J Stott - Clinical Genetics, 2023 - Wiley Online Library
Huntington Disease (HD) is an incurable autosomal dominant single gene
neurodegenerative disorder. Typical onset is between 30 and 40 years and characterised by …